Israeli biotech firm surges on mystery firm's nameless analyst note
Add BT as a preferred sourceTel Aviv
WHEN Pluristem Therapeutics Inc, an Israeli developer of experimental stem-cell treatments, rose 39 per cent in Nasdaq trading last week, traders attributed it to a bullish report on a website linked to a California biotech pundit.
The two-page report from Acceleron Equity Research dated Jan 26 was published on Acceleron's website and distributed by Marketwired, a press-release distribution service, the next day. The site and research document don't identify anyone involved with the firm, while the press release about the report lists a media contact named M Morhamus. The report says the analysts who wrote it don't own Pluristem stock, but that employees and officers of Acceleron might.
TRENDING NOW
Singapore data centre Reits chase Japan deals as power crunch raises stakes
Canada’s fight with the US has far bigger stakes than trade
Hell hath no fury like a man scorned: CEO’s S$468,000 suit against ex fails after relationship sours
Nike, Lululemon, Shein woes: A silver lining in Singapore’s lack of listed consumer brands
